A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Summary
- Eligibility
- for males ages 18-65 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here.
- ID
- NCT03861273
- Phase
- Phase 3 Hemophilia Research Study
- Study Type
- Interventional
- Participants
- Expecting 50 study participants
- Last Updated